S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Alessandra Ferrajoli,Susan O'Brien,William G. Wierda,Stefan Faderl,Steven M. Kornblau,Kimberly Yerrow,Zeev Estrov,Hagop M. Kantarjian,Michael J. Keating +8 more
TL;DR: Early results indicate that lenalidomide given as continuous therapy at a start dose of 5 mg followed by slow dose escalation is safe and well-tolerated as initial therapy by elderly patients with CLL.
Journal ArticleDOI
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Apostolia Maria Tsimberidou,Elihu H. Estey,Gary J. Whitman,Mark J. Dryden,Suresh Ratnam,Sherry Pierce,Stefan Faderl,Francis J. Giles,Hagop M. Kantarjian,Guillermo Garcia-Manero +9 more
TL;DR: A patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO is reported and the experience with patients with isolated extramingullary relapse in APL is summarized.
Journal ArticleDOI
T-cell prolymphocytic leukemia: a single-institution experience
Farhad Ravandi,Susan O'Brien,Dan Jones,Susan Lerner,Stefan Faderl,Alessandra Ferrajoli,William G. Wierda,Guillermo Garcia-Manero,Deborah A. Thomas,Charles Koller,Srdan Verstovsek,Francis J. Giles,Jorge E. Cortes,Marco Herling,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
Journal ArticleDOI
Prediction model for mortality after intracranial hemorrhage in patients with leukemia
Farshid Dayyani,Sarah Schellhorn Mougalian,Kiran Naqvi,Jianqin Shan,Farhad Ravandi,Jorge E. Cortes,Jeffrey S. Weinberg,Elias Jabbour,Stefan Faderl,William G. Wierda,Deborah A. Thomas,Susan O'Brien,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +14 more
TL;DR: Patients with leukemia who develop ICH do not have universally poor outcomes, and a simple scoring system could serve to advise physicians and families of the prognosis and the potential benefit of aggressive treatment options.
Journal ArticleDOI
Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
Hagop M. Kantarjian,Susan O'Brien,Guillermo Garcia-Manero,Stefan Faderl,Farhad Ravandi,Elias Jabbour,Jianqin Shan,Jorge E. Cortes +7 more
TL;DR: The long‐term outcome of patients with chronic phase chronic myeloid leukemia treated with imatinib after failure of interferon alpha therapy has not been detailed.